BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/17/2021 6:19:34 AM | Browse: 655 | Download: 1254
 |
Received |
|
2021-01-24 00:06 |
|
Peer-Review Started |
|
2021-01-24 00:10 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-10 05:28 |
|
Revised |
|
2021-02-11 21:35 |
|
Second Decision |
|
2021-03-10 10:10 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-03-11 02:54 |
|
Articles in Press |
|
2021-03-11 02:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-03-16 01:26 |
|
Publish the Manuscript Online |
|
2021-03-17 06:19 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Júlio Maria Fonseca Chebli, Natália Sousa Freitas Queiroz, Adérson Omar Mourão Cintra Damião, Liliana Andrade Chebli, Márcia Henriques de Magalhães Costa and Rogério Serafim Parra |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Rogério Serafim Parra, MD, PhD, Assistant Professor, Staff Physician, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900, Ribeirão Preto 14048-900, SP, Brazil. rsparra@hcrp.usp.br |
| Key Words |
Inflammatory bowel disease; SARS-CoV-2; COVID-19; Crohn disease; Colitis ulcerative; Biological therapy |
| Core Tip |
The knowledge on coronavirus disease 2019 (COVID-19) is rapidly evolving. Although patients with inflammatory bowel disease (IBD) do not appear to be at increased risk for COVID-19, the potential impact of immunosuppressive therapies on patients with IBD infected with severe acute respiratory syndrome coronavirus 2 calls for concern for clinicians and patients. Several recommendations and guidelines have recently been published, including the necessary reorganization of gastroenterology and endoscopy services to attendance of these patients, the growing role played by telemedicine, and the importance of addressing aspects of mental health in this context. We provide an overview and practical guidance for managing patients with IBD medically and surgically in the COVID-19 era. |
| Publish Date |
2021-03-17 06:19 |
| Citation |
Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i11/1022.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i11.1022 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
